A study conducted at the Duke Cancer Institute indicates that adding a tetanus short to another vaccine as a treatment option for glioblastoma, a lethal brain cancer, can have a profound effect on increasing a patient's life span. According to study author Kristen Batich, a dual medical-doctoral degree student at Duke University, the average survival period for a gliobastoma patient is 12 to 15 months; the addition of the tetanus shot caused patients to live "years longer than expected." While the Duke University study was conducted on a small scale, the findings put new forms of therapy into perspective.
To read more about this study, click here
No comments:
Post a Comment